ANGLE signs option agreement with Queen Mary University of London

Josh White Sharecast | 13 Sep, 2017 14:48 | | |

cash money sterling pound

Angle

35.50

17:17 22/09/17
0.00%
0.00
  • 7,803.58
  • 0.53%41.28
  • Max: 7,808.37
  • Min: 7,734.83
  • Volume: 0
  • MM 200 : n/a
17:30 22/09/17
  • 994.67
  • 0.30%2.94
  • Max: 995.03
  • Min: 989.98
  • Volume: 0
  • MM 200 : n/a
17:25 22/09/17

Liquid biopsy company ANGLE announced that it has signed an option agreement with Queen Mary University of London on Wednesday, for an exclusive worldwide licence over the use of its megakaryocyte intellectual property.

The AIM-traded firm said in June that QMUL had published research in Clinical Cancer Research using ANGLE's Parsortix system, showing that the number of megakaryocyte cells in the blood of prostate cancer patients correlated closely with increased patient survival.

It was the first time the presence of those cells in patient blood had been shown to be connected to cancer prognosis, ANGLE claimed.

“Investigation of megakaryocytes in patient blood opens up the potential for a whole new area for cancer diagnostics and, at present, ANGLE's patented Parsortix system is the only system that has demonstrated the capability of harvesting megakaryocytes,” the company’s board said in its statement.

QMUL had filed two patent applications in relation to the findings, which were being prosecuted worldwide.

ANGLE said it signed a two-year option to an exclusive worldwide licence to the patents covering any medical therapeutic, diagnostic, or prophylactic application, and agreeing to cover the costs of prosecution.

Through the deal, ANGLE now had intellectual property protection over the upstream cell capture technology - its existing Parsortix IP - and the downstream megakaryocyte analysis technology - via the option agreement.

Megakaryocyte analysis may provide medical insight in multiple cancer types, the board added, and Barts Cancer Institute - which is part of QMUL - is investigating other cancer types to substantiate that.

ANGLE said the Parsortix system had been shown to be capable of harvesting for analysis not only mesenchymal CTCs, which are linked to a poor outcome, but also megakaryocytes, which are linked to a “favourable” patient outcome.

Combining those two factors could provide new insights into patient condition.

“This deal further strengthens ANGLE's intellectual property position in the fast-emerging liquid biopsy market,” said ANGLe founder and chief executive Andrew Newland.

“Use of the Parsortix system is driving new discoveries by key opinion leaders and customers and ANGLE is the obvious partner to drive their commercialisation so we expect to see other similar developments over time continually strengthening the Company's position in the market.”

Michele Hill-Perkins, head of technology transfer biopharma at QMUL Barts Queen Mary Innovation, said her team believed the patents on the role of megakaryocytes in patient blood as a favourable prognostic biomarker had the potential to “open up” new avenues of research in the fight against cancer.

“We are delighted to have signed this deal with ANGLE to progress their commercialisation for the benefit of patients.”

More news

22 Sep Europe close: Stocks finish higher on strong PMI readings

Stocks on the Continent finished mostly higher on the back of strong survey readings on the euro area's manufacturing and services sector and ahead of the German general elections at the weekend, although fresh barbs from Pyongyang were a drag on sentiment.

22 Sep Thousands of steel workers protest ThyssenKrupp merger in Germany

Thousands of steel workers gathered in Western Germany on Friday to protest the proposed merger of ThyssenKrupp and Tata Steel's European operations which was expected to result in approximately 4,000 job losses.

22 Sep London Close: FTSE firmer as pound losses ground after May speech

London stocks had reversed earlier losses to trade a little higher by Friday's close, helped along by a weaker pound as investors weighed up a key speech by Prime Minister Theresa May.

22 Sep JP Morgan Chase to establish global headquarters in Warsaw

Polish Deputy Prime Minister Mateusz Morawiecki announced on Friday that US bank JP Morgan Chase had picked Warsaw to play host to its new global operations centre, bringing thousands of jobs to the region from the beginning of 2018.

22 Sep FTSE 250 movers: Pets at Home dashes higher, oilers also lifted

The FTSE 250 index was on the front foot on Friday, led by retailer Pets at Home and a group of oil-related companies.

22 Sep Theresa May calls for post-Brexit transition period, new security treaty

In a speech in Florence on Friday, Prime Minister Theresa May confirmed that she wanted a two-year "implementation period" post-Brexit and a new treaty with the European Union on security and justice.

22 Sep FTSE 100 movers: Johnson Matthey rallies again but Smiths drops on results

London's FTSE 100 was up 0.6% to 7,305.66 in afternoon trade on Friday as investors mulled over PM Theresa May's Brexit speech in Florence.

22 Sep Results round-up

Saga, the specialist provider of products and services for those over 50, reported solid growth of 5.5% in underlying profits before tax for the first half as it ordered a second new cruise ship amid high demand.

22 Sep US economy shows resilience in face of hurricanes - Markit

Business activity in the US picked up in September despite hurricanes Harvey and Irma, as growth in the manufacturing sector helped to offset an easing in services, according to preliminary data released on Friday.

22 Sep Thalassa suspends share buyback as FairfieldNodal commences due diligence

Thalassa Holdings confirmed the suspension of its share buyback programme on Friday, as a suitor continued to circle the marine geoscience and subsea robotics company.